Early discharge of hospitalised patients with community-acquired urosepsis when treated with levofloxacin in sequential therapy.

Author(s): Concia E, Marchetti F, LEVT07 Study Group

Affiliation(s): Department of Infectious Diseases, Policlinico G.B. Rossi, University of Verona, Verona, Italy.

Publication date & source: 2006-09, Arch Ital Urol Androl., 78(3):112-4.

Publication type: Research Support, Non-U.S. Gov't

OBJECTIVES: To compare the sequential therapy with levofloxacin with a standard treatment in the management of urosepsis. MATERIALS AND METHODS: It was a multicenter, randomized, open label, pilot trial in community acquired urosepsis carried out in 7 hospitals. Levofloxacin administered 500 mg twice a day intravenously and then orally was compared to piperacillin/tazobactam 4 g/0.5 g three times a day, both in combination with amikacin 7.5 mg/Kg twice a day, for a maximum of 14 days. Amikacin could be suspended between day 3-7. RESULTS: Both treatments were efficacious and well tolerated in the 47 enrolled patients, even tough the time to clinical stability was shorter in the levofloxacin treated patients (3.9 vs. 4.9 days). In the levofloxacin group the sequential therapy was performed in 19 (82.6%) cases, after 4.8 +/- 1.7 days of parenteral administration (100% in the per-protocol population after 5.1 +/- 1.9 days). CONCLUSIONS: The implementation of the sequential therapy in the levofloxacin group allowed an early hospital discharge in patients with urosepsis and a cost saving in the hospital perspective.